This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Polaris, 58.com, BlackRock, Intuitive Surgical, Medtronic and NuVasive as Zacks Bull and Bear of the Day
by Zacks Equity Research
Polaris, 58.com, BlackRock, Intuitive Surgical, Medtronic and NuVasive as Zacks Bull and Bear of the Day
3 Stocks to Tap the Minimally-Invasive Surgery Market Boom
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing minimally-invasive surgical device market.
Medical Device Firms in Focus on Expanded R&D Scope: 5 Picks
by Zacks Equity Research
The suspension of the Medical Device Tax, the evolution of mechatronics and big data in the MedTech space make some of the stocks lucrative picks for investment.
Walgreens Boots' Retail Pharmacy Strong Despite Several Woes
by Zacks Equity Research
Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.
Mechatronics for Healthcare: 3 MedTech Stocks to Bet On
by Nabaparna Bhattacharya
Here we analyze how Medical Mechatronics is creating new opportunities in MedTech for investors who are keen on putting their money in the healthcare space for longer-term gains.
QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth
by Zacks Equity Research
QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.
Medtronic's Expanded IN.PACT Admiral FDA Nod to Aid APV Arm
by Zacks Equity Research
Medtronic's (MDT) receipt of FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
Haemonetics' Plasma Momentum Solid, Margins Gain Traction
by Zacks Equity Research
Solid end-market demand for plasma-derived biopharmaceuticals continues to drive growth for Haemonetics (HAE).
ISRG or ITGR: Which is a Better Medical Instrument Stock?
by Zacks Equity Research
Intuitive Surgical (ISRG) and Integer Holdings' (ITGR) strong fundamentals and rising share price make them close contenders.
Here's Why You Should Steer Clear of Express Scripts for Now
by Zacks Equity Research
Express Scripts' (ESRX) loss of major customers, downbeat 2018 earnings guidance and selling of shares to Cigna make it lower its credibility as an investment pick.
Cardinal Health (CAH), CD&R to Jointly Invest in naviHealth
by Zacks Equity Research
Cardinal Health (CAH) intends to boost its acute-care program platform by jointly investing in the earlier acquired naviHealth along with Clayton, Dubilier & Rice.
SYK or SRDX: Which is a Better Medical Product Stock?
by Zacks Equity Research
Stryker (SYK) and Surmodics' (SRDX) strong fundamentals and rising share price make them close contenders.
3 Medical Instrument Stocks to Gain on Solid Market Prospects
by Zacks Equity Research
Here we take a peek at three Medical Instrument stocks that are likely to deliver strong returns in the days to come.
Here's Why You Should Buy Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian Medical's (VAR) solid product portfolio and strong global foothold make it a lucrative pick.
Medidata Solutions (MDSO) Rallies 10.4% on Solid Q1 Earnings
by Zacks Equity Research
Medidata Solutions (MDSO) reports strong Q1 earnings and solid growth across segments.
CVS Health's PBM Selling Season Remains Solid, Retail Grows
by Zacks Equity Research
CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.
Corindus Vascular Robotics (CVRS) Soars: Stock Adds 14.2% in Session
by Zacks Equity Research
Corindus Vascular Robotics (CVRS) saw a big move last session, as its shares jumped more than 14% on the day, amid huge volumes.
Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cooper (COO) witnesses strong growth across segments and geographies in fiscal Q2.
Bio-Rad Banks on Solid Global Scenario, Competition Rife
by Zacks Equity Research
Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.
Why You Should Add IDEXX (IDXX) Stock to Your Portfolio?
by Zacks Equity Research
IDEXX's (IDXX) stellar performance is primarily driven by robust sales at the CAG (Companion Animal Group) business.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.
ABMD or VAR: Which is a Better Medical Instrument Stock?
by Zacks Equity Research
It is pretty difficult for investors to choose from MedTech bigwigs Abiomed (ABMD) and Varian Medical (VAR) as both the companies are riding on solid estimate revision and other developments.
ResMed Reports Positive Results for Bilevel PAP Device Study
by Zacks Equity Research
Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.
Varian to Demonstrate Brachytherapy Solutions Portfolio
by Zacks Equity Research
Varian (VAR) will demonstrate four brachytherapy solutions in the American Brachytherapy Society Annual Meeting in San Francisco.
STERIS (STE) Benefits From Core Business Expansion, Buyouts
by Zacks Equity Research
STERIS' (STE) strong organic growth across specialty services, life sciences and applied sterilization segments raises optimism on the stock.